|
 Under the agreement, Sanofi will obtain global development and
commercialization rights to fitusiran, currently in development for
the treatment of people with hemophilia A and B.
Global commercialization of fitusiran will be done by Sanofi Genzyme,
the specialty care global business unit of Sanofi, while Alnylam
will receive royalties based on net sales of fitusiran products.
Fitusiran complements Sanofi Genzyme's rare hematology portfolio and
will bring an innovative new treatment for people living with
hemophilia, one of the most common rare diseases.
Alnylam will obtain global development and commercialization rights
to a new treatment of ATTR amyloidosis, a rare disease caused by the
build-up of an abnormal protein.
"The restructured alliance reflects Sanofi Genzyme's sustained
interest in the strong potential of Alnylam's portfolio of genetic
medicines," said Bill Sibold, Executive Vice President and Head of
Sanofi Genzyme.
[to top of second column] |
Sanofi said it will continue to have the right to opt into other
Alnylam rare genetic disease programs for development and
commercialization in territories outside of the United States,
Canada and Western Europe, as well as one right to a global license.
(Reporting by Geert De Clercq; Editing by Biju Dwarakanath)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
